GlobeNewswire All Public CompaniesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:30:00·⟳ 抓取 19:33:21·⚡ 决策 09-01 21:20:44 +1h47m·56.0 天前
Pyxis Oncology宣布参加三场投资者会议，未披露业务或临床新增进展
事件只是会议出席安排和网络直播信息，未改变公司资产状态、商业化前景、融资预期或短期基本面，缺少可交易增量。
📄 原文GlobeNewswire All Public Companies↗ 原文
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing nex…
不做 Pyxis Oncology, Inc.（PYXS.US）
不做：当前公告只是投资者会议日程，未披露临床、监管、合作、融资或财务新增事实，方向和edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pyxis Oncology公告参加三场医疗投资者会议，但正文没有披露MICVO临床读数、FDA沟通、合作授权、融资或业绩指引等可改变估值的新增事实；会议本身可能带来后续信息披露，但当前事件不能支持做多或做空。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 medium ↗
主要风险
- 后续会议若披露临床数据、合作或融资信息，可能成为新的独立催化，但不属于本公告已确认事实。
- 临床阶段小市值生物医药股对会议表述和融资预期敏感，当前无明确新增事实时追交易容易变成事件噪音。
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论；核心原因是事件本身缺少新增事实。
方向:会议日程公告不构成可量化事件机制，历史先例对当前交易方向帮助有限。
涨幅量级:未使用先例校准幅度，因为当前事件没有基本面增量或明确交易方向。
形态:不适用。
原文全文
展开原文 · 2,540 字
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.
Wells Fargo 21
st
Annual Healthcare Conference
in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.
2026 Cantor Global Healthcare Conference
in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.
H.C. Wainwright 28
th
Annual Global Investment Conference
in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET.
Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website,
ir.pyxisoncology.com
.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
To learn more, visit
www.pyxisoncology.com
or follow us on
LinkedIn
.
Pyxis Oncology Contact
IR@pyxisoncology.com
Wells Fargo 21
st
Annual Healthcare Conference
in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.
2026 Cantor Global Healthcare Conference
in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.
H.C. Wainwright 28
th
Annual Global Investment Conference
in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET.
Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website,
ir.pyxisoncology.com
.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
To learn more, visit
www.pyxisoncology.com
or follow us on
.
Pyxis Oncology Contact
IR@pyxisoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。